Corporate
2022.03.15
Lumosa to Attend Bio-Europe Spring
Corporate
2022.01.27
Lumosa to Present LT3001 at the International Stroke Conference 2022
Corporate
2022.01.11
Lumosa Receives U.S. FDA Fast Track Designation for Its LT3001, a Novel Drug for the Treatment of Acute Ischemic Stroke
Corporate
2021.12.29
Lumosa Receives Market Approval for Its Long-Acting Analgesic Injection from Thailand
Corporate
2021.12.24
Phase 2 IND for Lumosa's Novel Stroke Therapy Approved by Taiwan FDA
A Multiple-dose of LT3001 to be Administered in Combination with Mechanical Thrombectomy
Corporate
2021.11.16
LT1001 Formulation Patent Granted by JPO